Quantification Of Angiogenesis In Cervical Cancer: A Comparison Among Three Endothelial Cell Markers.

dc.creatorVieira, Sabas Carlos
dc.creatorZeferino, Luiz Carlos
dc.creatorDa Silva, Benedito Borges
dc.creatorAparecida Pinto, Glauce
dc.creatorVassallo, José
dc.creatorCarasan, Gislaine Aparecida Fonsechi
dc.creatorDe Moraes, Natália Guimarães
dc.date2004-Apr
dc.date2015-11-27T12:58:50Z
dc.date2015-11-27T12:58:50Z
dc.date.accessioned2018-03-29T01:00:29Z
dc.date.available2018-03-29T01:00:29Z
dc.identifierGynecologic Oncology. v. 93, n. 1, p. 121-4, 2004-Apr.
dc.identifier0090-8258
dc.identifier10.1016/j.ygyno.2004.01.033
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/15047224
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/196176
dc.identifier15047224
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1296409
dc.descriptionThe aim of this study was to evaluate the quantification of angiogenesis by assessing microvessel density in cervical cancer, comparing the performance of three monoclonal antibodies: anti-CD34 and BNH9, which are still little known markers in cervical neoplasia, and anti-CD31. Fifty-four consecutive patients diagnosed with stages I and II invasive cervical cancer undergoing radical hysterectomy and bilateral pelvic lymphadenectomy were evaluated. The monoclonal primary antibodies used were anti-CD34, anti-CD31 and BNH9 antibody. The areas of highest microvessel density were used for counting microvessels in 10 high-power fields. Microvessel density was the mean vessel number counted in 10 high-power fields. The mean of microvessel density was 10.3, 9.7 and 5.8 for anti-CD34, BNH9 and anti-CD31, respectively. According to the Kruskal-Wallis nonparametric test, microvessel density estimated by anti-CD34 and BNH9 was significantly higher than the microvessel density estimated by anti-CD31. The difference between microvessel density measured by anti-CD34 and BNH9 was not statistically significant. There was diagnostic agreement in 44 out of 54 cases for anti-CD34 and BNH9 monoclonal antibodies, kappa coefficient being 0.63. The kappa coefficient was 0.41 between anti-CD34 and anti-CD31 and 0.26 between anti-CD31 and BNH9. The anti-CD34 and BNH9 seem to have higher sensitivity than anti-CD31. The agreement to quantify microvessel density between anti-CD34 and BNH9 is higher than between them and anti-CD31. Additionally, considering that the BNH9 is much less unknown than anti-CD34 and that they showed very similar performance, the BNH9 clinical significance should be test in different neoplasms.
dc.description93
dc.description121-4
dc.languageeng
dc.relationGynecologic Oncology
dc.relationGynecol. Oncol.
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAdult
dc.subjectAged
dc.subjectAntibodies, Monoclonal
dc.subjectAntigens, Cd31
dc.subjectAntigens, Cd34
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunohistochemistry
dc.subjectMiddle Aged
dc.subjectNeoplasm Staging
dc.subjectNeovascularization, Pathologic
dc.subjectUterine Cervical Neoplasms
dc.titleQuantification Of Angiogenesis In Cervical Cancer: A Comparison Among Three Endothelial Cell Markers.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución